Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial

The combination of lenalidomide and low-dose dexamethasone is an effective treatment for multiple myeloma (MM). Addition of alkylating agents to lenalidomide or thalidomide results in increased response rates and deeper responses. We designed this trial to study the combination of cyclophosphamide,...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kumar, Shaji K., Lacy, Martha Q., Hayman, Suzanne R., Stewart, Keith, Buadi, Francis K., Allred, Jacob, Laumann, Kristina, Greipp, Philip R., Lust, John A., Gertz, Morie A., Zeldenrust, Steven R., Bergsagel, P. Leif, Reeder, Craig B., Witzig, Thomas E., Fonseca, Rafael, Russell, Stephen J., Mikhael, Joseph R., Dingli, David, Rajkumar, S. Vincent, Dispenzieri, Angela
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3901994/
https://ncbi.nlm.nih.gov/pubmed/21630308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.22053
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires